• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

调节非小细胞肺癌患者骨骼肌质量损失率的因素:一项初步研究。

Factors which modulate the rates of skeletal muscle mass loss in non-small cell lung cancer patients: a pilot study.

作者信息

Atlan Philippe, Bayar Mohamed Amine, Lanoy Emilie, Besse Benjamin, Planchard David, Ramon Jordy, Raynard Bruno, Antoun Sami

机构信息

Département Interdisciplinaire de Soins de Support, Gustave-Roussy, Université Paris-Saclay, 114 rue Edouard Vaillant, F-94805, Villejuif, France.

Service de Biostatistique et d'Epidémiologie, Gustave-Roussy, Université Paris-Saclay, F-94805, Villejuif, France.

出版信息

Support Care Cancer. 2017 Nov;25(11):3365-3373. doi: 10.1007/s00520-017-3755-z. Epub 2017 Jun 8.

DOI:10.1007/s00520-017-3755-z
PMID:28593463
Abstract

PURPOSE

Advanced non-small cell lung cancer (NSCLC) is associated with weight loss which may reflect skeletal muscle mass (SMM) and/or total adipose tissue (TAT) depletion. This study aimed to describe changes in body composition (BC) parameters and to identify the factors unrelated to the tumor which modulate them.

METHODS

SMM, TAT, and the proportion of SMM to SMM + TAT were assessed with computed tomography. Estimates of each BC parameter at follow-up initiation and across time were derived from a mixed linear model of repeated measurements with a random intercept and a random slope. The same models were used to assess the independent effect of gender, age, body mass index (BMI), and initial values on changes in each BC parameter.

RESULTS

Sixty-four patients with stage III or IV NSCLC were reviewed. The mean ± SD decreases in body weight and SMM were respectively 59 ± 3 g/week (P < 0.03) and 7 mm/m/week (P = 0.0003). During follow-up, no changes were identified in TAT nor in muscle density or in the proportion of SMM to SMM + TAT, estimated at 37 ± 2% at baseline. SMM loss was influenced by initial BMI (P < 0.0001) and SMM values (P = 0.0002): the higher the initial BMI or SMM values, the greater the loss observed. Weight loss was greater when the initial weight was heavier (P < 0.0001).

CONCLUSION

Our results demonstrate that SMM wasting in NSCLC is lower when initial SMM and BMI values are low. These exploratory findings after our attempt to better understand the intrinsic factors associated with muscle mass depletion need to be confirmed in larger studies.

摘要

目的

晚期非小细胞肺癌(NSCLC)与体重减轻有关,这可能反映骨骼肌质量(SMM)和/或总脂肪组织(TAT)的消耗。本研究旨在描述身体成分(BC)参数的变化,并确定与肿瘤无关的调节这些参数的因素。

方法

采用计算机断层扫描评估SMM、TAT以及SMM占SMM+TAT的比例。随访开始时及随访期间各BC参数的估计值来自具有随机截距和随机斜率的重复测量混合线性模型。相同的模型用于评估性别、年龄、体重指数(BMI)和初始值对每个BC参数变化的独立影响。

结果

对64例III期或IV期NSCLC患者进行了回顾性分析。体重和SMM的平均±标准差下降分别为59±3g/周(P<0.03)和7mm/m/周(P=0.0003)。随访期间,未发现TAT、肌肉密度或SMM占SMM+TAT的比例有变化,基线时估计为37±2%。SMM的损失受初始BMI(P<0.0001)和SMM值(P=0.0002)的影响:初始BMI或SMM值越高,观察到的损失越大。初始体重越重,体重减轻越明显(P<0.0001)。

结论

我们的结果表明,当初始SMM和BMI值较低时,NSCLC患者的SMM消耗较少。在我们试图更好地理解与肌肉质量消耗相关的内在因素后得出的这些探索性发现,需要在更大规模的研究中得到证实。

相似文献

1
Factors which modulate the rates of skeletal muscle mass loss in non-small cell lung cancer patients: a pilot study.调节非小细胞肺癌患者骨骼肌质量损失率的因素:一项初步研究。
Support Care Cancer. 2017 Nov;25(11):3365-3373. doi: 10.1007/s00520-017-3755-z. Epub 2017 Jun 8.
2
The association between skeletal muscle measures and chemotherapy-induced toxicity in non-small cell lung cancer patients.骨骼肌测量与非小细胞肺癌患者化疗诱导毒性的关系。
J Cachexia Sarcopenia Muscle. 2022 Jun;13(3):1554-1564. doi: 10.1002/jcsm.12967. Epub 2022 Mar 18.
3
Staging of nutrition disorders in non-small-cell lung cancer patients: utility of skeletal muscle mass assessment.非小细胞肺癌患者营养障碍的分期:骨骼肌质量评估的效用。
J Cachexia Sarcopenia Muscle. 2019 Aug;10(4):782-793. doi: 10.1002/jcsm.12418. Epub 2019 Apr 1.
4
Sarcopenic obesity by the ESPEN/EASO criteria for predicting mortality in advanced non-small cell lung cancer.根据 ESPEN/EASO 标准,肌少症性肥胖可预测晚期非小细胞肺癌患者的死亡率。
Clin Nutr. 2023 Jun;42(6):817-824. doi: 10.1016/j.clnu.2023.04.010. Epub 2023 Apr 13.
5
Impact of low skeletal muscle mass on non-lung cancer mortality after stereotactic body radiotherapy for patients with stage I non-small cell lung cancer.低骨骼肌量对Ⅰ期非小细胞肺癌立体定向体部放疗后非肺癌死亡率的影响。
J Geriatr Oncol. 2018 Nov;9(6):589-593. doi: 10.1016/j.jgo.2018.05.003. Epub 2018 May 18.
6
No evidence for changes in skeletal muscle mass or weight during first-line chemotherapy for metastatic colorectal cancer.在转移性结直肠癌的一线化疗期间,没有证据表明骨骼肌质量或体重发生变化。
BMC Cancer. 2019 Aug 28;19(1):847. doi: 10.1186/s12885-019-6086-2.
7
Single-institution study of correlations between skeletal muscle mass, its density, and clinical outcomes in non-small cell lung cancer patients treated with first-line chemotherapy.一项关于一线化疗治疗的非小细胞肺癌患者骨骼肌量、密度与其临床结局相关性的单中心研究。
Thorac Cancer. 2018 Dec;9(12):1623-1630. doi: 10.1111/1759-7714.12870. Epub 2018 Sep 27.
8
Prognostic impact of cancer cachexia in patients with advanced non-small cell lung cancer.癌症恶病质对晚期非小细胞肺癌患者的预后影响
Support Care Cancer. 2015 Jun;23(6):1699-708. doi: 10.1007/s00520-014-2534-3. Epub 2014 Nov 29.
9
Enhancing evaluation of sarcopenia in patients with non-small cell lung cancer (NSCLC) by assessing skeletal muscle index (SMI) at the first lumbar (L1) level on routine chest computed tomography (CT).通过在常规胸部计算机断层扫描(CT)上评估第一腰椎(L1)水平的骨骼肌指数(SMI),增强对非小细胞肺癌(NSCLC)患者的肌肉减少症评估。
Support Care Cancer. 2018 Jul;26(7):2353-2359. doi: 10.1007/s00520-018-4051-2. Epub 2018 Feb 7.
10
Skeletal muscle radiodensity is prognostic for survival in patients with advanced non-small cell lung cancer.骨骼肌放射密度对晚期非小细胞肺癌患者的生存具有预后价值。
Clin Nutr. 2016 Dec;35(6):1386-1393. doi: 10.1016/j.clnu.2016.03.010. Epub 2016 Apr 1.

引用本文的文献

1
Malnutrition risk as a predictor of quality of life and skeletal muscle depletion following upper gastrointestinal cancer diagnosis: A longitudinal analysis.营养不良风险作为上消化道癌诊断后生活质量和骨骼肌消耗的预测指标:一项纵向分析。
J Nutr Health Aging. 2025 Jul 1;29(9):100623. doi: 10.1016/j.jnha.2025.100623.
2
A Mathematical Model of the Disruption of Glucose Homeostasis in Cancer Patients.癌症患者葡萄糖内稳态破坏的数学模型。
Bull Math Biol. 2023 May 27;85(7):58. doi: 10.1007/s11538-023-01146-3.
3
Predicting muscle loss during lung cancer treatment (PREDICT): protocol for a mixed methods prospective study.

本文引用的文献

1
Sarcopenia is Associated with Chemotherapy Toxicity in Patients Undergoing Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis from Colorectal Cancer.肌肉减少症与接受结直肠癌腹膜转移瘤细胞减灭术联合热灌注化疗患者的化疗毒性相关。
Ann Surg Oncol. 2016 Nov;23(12):3891-3898. doi: 10.1245/s10434-016-5360-7. Epub 2016 Jun 28.
2
Relationship between efficacy outcomes and weight gain during treatment of advanced, non-squamous, non-small-cell lung cancer patients.晚期非鳞状非小细胞肺癌患者治疗期间疗效结局与体重增加的关系。
Ann Oncol. 2016 Aug;27(8):1612-9. doi: 10.1093/annonc/mdw211. Epub 2016 May 23.
3
预测肺癌治疗期间肌肉减少症(PREDICT):一项混合方法前瞻性研究方案。
BMJ Open. 2021 Sep 27;11(9):e051665. doi: 10.1136/bmjopen-2021-051665.
4
Chemotherapy-Induced Sarcopenia.化疗相关性肌肉减少症。
Curr Treat Options Oncol. 2020 Jan 30;21(1):7. doi: 10.1007/s11864-019-0691-9.
5
Loss of skeletal muscle index and survival in patients with metastatic colorectal cancer: Secondary analysis of the phase 3 CAIRO3 trial.转移性结直肠癌患者骨骼肌指数降低与生存:III 期 CAIRO3 试验的二次分析。
Cancer Med. 2020 Feb;9(3):1033-1043. doi: 10.1002/cam4.2787. Epub 2019 Dec 18.
6
No evidence for changes in skeletal muscle mass or weight during first-line chemotherapy for metastatic colorectal cancer.在转移性结直肠癌的一线化疗期间,没有证据表明骨骼肌质量或体重发生变化。
BMC Cancer. 2019 Aug 28;19(1):847. doi: 10.1186/s12885-019-6086-2.
7
Factors Contributing to Cancer-Related Muscle Wasting During First-Line Systemic Treatment for Metastatic Colorectal Cancer.转移性结直肠癌一线全身治疗期间导致癌症相关肌肉消耗的因素
JNCI Cancer Spectr. 2019 Apr 25;3(2):pkz014. doi: 10.1093/jncics/pkz016. eCollection 2019 Jun.
8
Early Skeletal Muscle Loss in Non-Small Cell Lung Cancer Patients Receiving Chemoradiation and Relationship to Survival.接受放化疗的非小细胞肺癌患者的早期骨骼肌丢失与生存的关系。
Support Care Cancer. 2019 Jul;27(7):2657-2664. doi: 10.1007/s00520-018-4563-9. Epub 2018 Nov 26.
9
Single-institution study of correlations between skeletal muscle mass, its density, and clinical outcomes in non-small cell lung cancer patients treated with first-line chemotherapy.一项关于一线化疗治疗的非小细胞肺癌患者骨骼肌量、密度与其临床结局相关性的单中心研究。
Thorac Cancer. 2018 Dec;9(12):1623-1630. doi: 10.1111/1759-7714.12870. Epub 2018 Sep 27.
10
Nutritional Status in Patients with Gastrointestinal Cancer in Comparison To Other Cancers In Shiraz, Southern Iran: a Case-Control Study.伊朗南部设拉子地区胃肠道癌患者与其他癌症患者的营养状况比较:一项病例对照研究
World J Plast Surg. 2018 May;7(2):186-192.
Skeletal Muscle Changes After Elective Colorectal Cancer Resection: A Longitudinal Study.
择期结直肠癌切除术后的骨骼肌变化:一项纵向研究
Ann Surg Oncol. 2016 Aug;23(8):2539-47. doi: 10.1245/s10434-016-5188-1. Epub 2016 Mar 22.
4
Prognostic Significance of Muscle Attenuation in Pancreatic Cancer Patients Treated with Neoadjuvant Chemoradiotherapy.新辅助放化疗治疗的胰腺癌患者肌肉衰减的预后意义
World J Surg. 2015 Dec;39(12):2975-82. doi: 10.1007/s00268-015-3205-3.
5
Changes in skeletal muscle mass during palliative chemotherapy in patients with advanced lung cancer.晚期肺癌患者姑息化疗期间骨骼肌质量的变化
Acta Oncol. 2015 Mar;54(3):340-8. doi: 10.3109/0284186X.2014.953259. Epub 2014 Sep 16.
6
Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.全球癌症发病与死亡:GLOBOCAN 2012 数据源、方法与主要模式。
Int J Cancer. 2015 Mar 1;136(5):E359-86. doi: 10.1002/ijc.29210. Epub 2014 Oct 9.
7
Loss of muscle mass in the end of life in patients with advanced cancer.晚期癌症患者临终时肌肉质量的丧失。
Support Care Cancer. 2015 Jan;23(1):79-86. doi: 10.1007/s00520-014-2332-y. Epub 2014 Jul 1.
8
Epidemiology of lung cancer.肺癌流行病学
Semin Intervent Radiol. 2013 Jun;30(2):93-8. doi: 10.1055/s-0033-1342949.
9
The assessment and impact of sarcopenia in lung cancer: a systematic literature review.肺癌中肌肉减少症的评估与影响:一项系统文献综述
BMJ Open. 2014 Jan 2;4(1):e003697. doi: 10.1136/bmjopen-2013-003697.
10
Low skeletal muscle is associated with toxicity in patients included in phase I trials.低骨骼肌量与纳入I期试验的患者的毒性相关。
Invest New Drugs. 2014 Apr;32(2):382-7. doi: 10.1007/s10637-013-0053-6. Epub 2013 Dec 17.